Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

1. Slamon, D.J.
2. Neven, P.
3. Chia, S.
4. Jerusalem, G.
5. De Laurentiis, M.
6. Im, S.
7. Petrakova, K.
8. Valeria Bianchi, G.
9. Martín, M.
10. Nusch, A.
11. Sonke, G.S.
12. De la Cruz-Merino, L.
13. Beck, J.T.
14. Ji, Y.
15. Wang, C.
16. Deore, U.
17. Chakravartty, A.
18. Zarate, J.P.
19. Taran, T.
20. Fasching, P.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.ANNONC.2021.05.353 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus